Upgrade to SI Premium - Free Trial

Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2015

October 29, 2015 4:30 PM

MECHANICSBURG, Pa., Oct. 29, 2015 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM) today announced results for its third quarter ended September 30, 2015.

For the third quarter ended September 30, 2015, net operating revenues increased 34.7% to $1,021.1 million, compared to $758.1 million for the same quarter, prior year. Income from operations was $48.2 million for the third quarter ended September 30, 2015, compared to $66.0 million for the same quarter, prior year. Income before income taxes included a non-operating, one-time gain of $29.6 million on the sale of an equity investment in the third quarter ended September 30, 2015. Net income attributable to Select Medical was $29.4 million for the third quarter ended September 30, 2015, compared to $26.5 million for the same quarter, prior year. Net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Concentra acquisition costs, equity in earnings (losses) of unconsolidated subsidiaries, and gain on sale of equity investment ("Adjusted EBITDA") for the third quarter ended September 30, 2015 decreased to $84.5 million, compared to $86.8 million for the same quarter, prior year. A reconciliation of net income to Adjusted EBITDA is presented in table VIII of this release. Income per common share for the third quarter ended September 30, 2015 was $0.22 on a fully diluted basis compared to income per common share of $0.20 for the same quarter, prior year.

For the nine months ended September 30, 2015, net operating revenues increased 17.9% to $2,703.5 million compared to $2,293.4 million for the same period, prior year. Income from operations was $212.5 million for the nine months ended September 30, 2015, compared to $226.7 million for the same period, prior year. Income before income taxes included a non-operating, one-time gain of $29.6 million on the sale of an equity investment in the nine months ended September 30, 2015. Net income attributable to Select Medical was $101.4 million for the nine months ended September 30, 2015, compared to $94.9 million for the same period, prior year. Net income attributable to Select Medical for the nine months ended September 30, 2014 includes a loss on early retirement of debt, net of tax, of $1.4 million. Adjusted EBITDA for the nine months ended September 30, 2015 increased 4.7% to $298.3 million compared to $285.0 million for the same period, prior year. A reconciliation of net income to Adjusted EBITDA is presented in table VIII of this release. Income per common share for the nine months ended September 30, 2015 was $0.77 on a fully diluted basis compared to income per common share of $0.71 for the nine months ended September 30, 2014. Excluding the loss related to the early retirement of debt and the related tax effect, adjusted income per common share was $0.72 per diluted share for the nine months ended September 30, 2014. A reconciliation of net income per common share to adjusted income per common share for the nine months ended September 30, 2014 is presented in table IX of this release.

Specialty Hospital Segment

For the third quarter ended September 30, 2015, net operating revenues for the specialty hospital segment increased 1.1% to $562.3 million, compared to $556.3 million for the same quarter, prior year. Adjusted EBITDA for the specialty hospital segment decreased to $53.7 million for the third quarter ended September 30, 2015, compared to $81.0 million for the same quarter, prior year. The Adjusted EBITDA margin for the segment was 9.5% for the third quarter ended September 30, 2015, compared to 14.6% for the same quarter, prior year. The Adjusted EBITDA results for the specialty hospital segment include start-up losses of approximately $3.1 million for the third quarter ended September 30, 2015 and $3.9 million for the same quarter, prior year. Certain specialty hospital key statistics for both the third quarter ended September 30, 2015 and 2014 are presented in table VI of this release.

For the nine months ended September 30, 2015, net operating revenues for the specialty hospital segment increased 4.4% to $1,753.4 million, compared to $1,678.8 million for the same period, prior year. Adjusted EBITDA for the specialty hospital segment for the nine months ended September 30, 2015 decreased to $241.6 million, compared to $261.8 million for the same period, prior year. The Adjusted EBITDA margin for the segment was 13.8% for the nine months ended September 30, 2015, compared to 15.6% for the same period, prior year. The Adjusted EBITDA results for the specialty hospital segment include start-up losses of approximately $11.9 million for the nine months ended September 30, 2015 and $8.6 million for the same period, prior year. Certain specialty hospital key statistics for both the nine months ended September 30, 2015 and 2014 are presented in table VII of this release.

Outpatient Rehabilitation Segment

For the third quarter ended September 30, 2015, net operating revenues for the outpatient rehabilitation segment decreased to $199.6 million, compared to $201.7 million for the same quarter, prior year. Adjusted EBITDA for the outpatient rehabilitation segment increased 3.5% to $23.8 million for the third quarter ended September 30, 2015, compared to $23.0 million for the same quarter, prior year. The Adjusted EBITDA margin for the segment was 11.9% for the third quarter ended September 30, 2015, compared to 11.4% for the same quarter, prior year. Certain outpatient rehabilitation key statistics for both the third quarter ended September 30, 2015 and 2014 are presented in table VI of this release.

For the nine months ended September 30, 2015, net operating revenues for the outpatient rehabilitation segment decreased to $603.8 million, compared to $614.4 million for the same period, prior year. Adjusted EBITDA for the outpatient rehabilitation segment for the nine months ended September 30, 2015 increased 0.3% to $74.7 million, compared to $74.4 million for the same period, prior year. The Adjusted EBITDA margin for the segment was 12.4% for the nine months ended September 30, 2015, compared to 12.1% for the same period, prior year. Certain outpatient rehabilitation key statistics for both the nine months ended September 30, 2015 and 2014 are presented in table VII of this release.

Concentra Segment

On June 1, 2015, MJ Acquisition Corporation, a joint venture that Select Medical created with Welsh, Carson, Anderson & Stowe XII, L.P. ("WCAS"), consummated the acquisition of Concentra Inc. ("Concentra"), which provides occupational health, consumer health, physical therapy, and veteran's healthcare services throughout the United States. Select Medical owns 50.1% of the voting interests of Concentra Group Holdings, LLC, the indirect parent of Concentra. Concentra's financial results are consolidated with Select Medical's effective June 1, 2015.

For the third quarter ended September 30, 2015, net operating revenues for the Concentra segment were $259.0 million. Adjusted EBITDA for the Concentra segment was $25.6 million for the third quarter ended September 30, 2015. The Adjusted EBITDA margin for the Concentra segment was 9.9% for the third quarter ended September 30, 2015. Certain Concentra key statistics for the third quarter ended September 30, 2015 are presented in table VI of this release.

For the period beginning June 1, 2015 through September 30, 2015, net operating revenues for the Concentra segment were $345.8 million. Adjusted EBITDA for the Concentra segment was $36.8 million for the period ended September 30, 2015. The Adjusted EBITDA margin for the Concentra segment was 10.6% for the period ended September 30, 2015. Certain Concentra key statistics for the period ended September 30, 2015 are presented in table VII of this release.

Stock Repurchase Program

The board of directors of Select Medical has authorized a $500.0 million stock repurchase program that will remain in effect until December 31, 2016, unless extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate. Select Medical is funding this program with cash on hand and borrowings under Select's revolving facility. During the three and nine months ended September 30, 2015, Holdings repurchased 1,032,334 shares at a cost of approximately $13.6 million, an average cost per share of $13.20, which includes transaction costs. Since the inception of the program through September 30, 2015, Holdings has repurchased 35,924,128 shares at a cost of approximately $314.7 million, or $8.76 per share, which includes transaction costs.

Business Outlook

Select Medical is updating its most recent business outlook after reporting third quarter 2015 financial performance. We now expect for the full year of 2015 consolidated net operating revenues to be in the range of $3.675 billion to $3.725 billion, Adjusted EBITDA in the range of $400.0 million to $410.0 million and fully diluted income per common share for the full year 2015 to be in the range of $0.92 to $0.97.

The Concentra segment is expected to contribute approximately $575.0 million of net operating revenues, approximately $55.0 million of Adjusted EBITDA and approximately $0.01 fully diluted income per common share, which amounts are included in the above revised business outlook.

Select Medical's business outlook includes expected Adjusted EBITDA start-up losses during the full year 2015 of approximately $17.0 million at Select Medical's long term acute care hospitals and inpatient rehabilitation facilities recently opened or under development.

Conference Call

Select Medical will host a conference call regarding its third quarter results and its business outlook on Friday, October 30, 2015, at 9:00am EDT. The domestic dial in number for the call is 1-877-474-9506. The international dial in number is 1-857-244-7559. The passcode for the call is 13517703. The conference call will be webcast simultaneously and can be accessed at Select Medical's website www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 11:59pm EST, November 6, 2015. The replay number is 1-888-286-8010 (domestic) or 1-617-801-6888 (international). The passcode for the replay will be 47193544. The replay can also be accessed at Select Medical's website, www.selectmedicalholdings.com.

Select Medical began operations in 1997 and has grown to be one of the largest operators of specialty hospitals and outpatient rehabilitation clinics in the United States based on number of facilities. On June 1, 2015, a joint venture created by Select Medical and WCAS consummated the acquisition of Concentra, which provides occupational health, consumer health, physical therapy, and veteran's healthcare services throughout the United States. As of September 30, 2015, Select Medical operated 110 long term acute care hospitals and 17 acute medical rehabilitation hospitals in 28 states, and 1,033 outpatient rehabilitation clinics in 31 states and the District of Columbia. Select Medical's contract therapy business provides medical rehabilitation services on a contracted basis to nursing homes, hospitals, assisted living and senior care centers, schools, and work sites. Concentra operated 300 centers in 38 states. Concentra also provides contract services at employer worksites and Department of Veterans Affairs community-based outpatient clinics. Select Medical had operations in 46 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

  • changes in government reimbursement for our services due to the implementation of healthcare reform legislation, deficit reduction measures, and/or new payment policies (including, for example, the expiration of the moratorium limiting the full application of the 25 Percent Rule that would reduce our Medicare payments for those patients admitted to a long term acute care hospital from a referring hospital in excess of an applicable percentage admissions threshold) may result in a reduction in net operating revenues, an increase in costs and a reduction in profitability;
  • the impact of the Bipartisan Budget Act of 2013, which establishes new payment limits for Medicare patients who do not meet specified criteria, may result in a reduction in net operating revenues and profitability of our long term acute care hospitals;
  • the failure of our specialty hospitals to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;
  • the failure of our facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;
  • a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
  • acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;
  • our plans and expectations related to the Concentra acquisition, including expectations regarding the expected capital expenditures related to the acquisition, and our ability to realize anticipated synergies;
  • private third-party payors for our services may undertake future cost containment initiatives that could limit our future net operating revenues and profitability;
  • the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;
  • shortages in qualified nurses, therapists, physicians, or other licensed providers could increase our operating costs significantly or limit our ability to staff our facilities;
  • competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;
  • the loss of key members of our management team could significantly disrupt our operations;
  • the effect of claims asserted against us could subject us to substantial uninsured liabilities; and
  • other factors discussed from time to time in our filings with the Securities and Exchange Commission, including factors discussed under the heading "Risk Factors" of our quarterly report on Form 10-Q and of the annual report on Form 10-K.

Investor inquiries:Joel T. VeitSenior Vice President and Treasurer717-972-1100[email protected]

I. Condensed Consolidated Statements of Operations

For the Three Months Ended September 30, 2014 and 2015

(In thousands, except per share amounts, unaudited)

2014

2015

% Change

Net operating revenues

$ 758,069

$ 1,021,123

34.7%

Costs and expenses:

Cost of services

644,392

900,949

39.8%

General and administrative

19,719

22,201

12.6%

Bad debt expense

10,357

18,287

76.6%

Depreciation and amortization

17,584

31,472

79.0%

Income from operations

66,017

48,214

(27.0)%

Equity in earnings of unconsolidated subsidiaries

1,988

6,348

219.3%

Gain on sale of equity investment

-

29,647

N/M

Interest expense

(21,753)

(33,052)

51.9%

Income before income taxes

46,252

51,157

10.6%

Income tax expense

17,956

18,347

2.2%

Net income

28,296

32,810

16.0%

Less: Net income attributable to non-

controlling interests

1,766

3,404

92.8%

Net income attributable to Select Medical

Holdings Corporation

$ 26,530

$ 29,406

10.8%

Weighted average shares outstanding(1):

Basic

126,639

127,386

Diluted

127,029

127,649

Income per common share(1):

Basic

$ 0.20

$ 0.22

Diluted

$ 0.20

$ 0.22

Dividends paid per share

$ 0.10

$ -

(1) Under the two-class method for calculating income per common share, unvested restricted stock is a separate, participating class. Income per common share and weighted average common shares outstanding exclude amounts attributed to the unvested restricted class of stockholders. Net income allocated to the unvested restricted stockholders was $0.9 million and $0.8 million for the three months ended September 30, 2015 and 2014, respectively. Unvested restricted weighted average shares were 4,127 thousand and 3,978 thousand for the three months ended September 30, 2015 and 2014, respectively.

N/M- Not Meaningful

II. Condensed Consolidated Statements of Operations

For the Nine Months Ended September 30, 2014 and 2015

(In thousands, except per share amounts, unaudited)

2014

2015

% Change

Net operating revenues

$ 2,293,409

$ 2,703,531

17.9%

Costs and expenses:

Cost of services

1,926,037

2,309,213

19.9%

General and administrative

57,219

67,917

18.7%

Bad debt expense

32,490

43,243

33.1%

Depreciation and amortization

51,009

70,668

38.5%

Income from operations

226,654

212,490

(6.2)%

Loss on early retirement of debt

(2,277)

-

N/M

Equity in earnings of unconsolidated subsidiaries

4,135

12,788

209.3%

Gain on sale of equity investment

-

29,647

N/M

Interest expense

(64,032)

(79,728)

24.5%

Income before income taxes

164,480

175,197

6.5%

Income tax expense

63,823

65,048

1.9%

Net income

100,657

110,149

9.4%

Less: Net income attributable to non-

controlling interests

5,742

8,740

52.5%

Net income attributable to Select Medical

Holdings Corporation

$ 94,915

$ 101,409

6.8%

Weighted average shares outstanding(1):

Basic

129,706

127,541

Diluted

130,177

127,844

Income per common share(1):

Basic

$ 0.71

$ 0.77

Diluted

$ 0.71

$ 0.77

Dividends paid per share

$ 0.30

$ 0.10

(1) Under the two-class method for calculating income per common share, unvested restricted stock is a separate, participating class. Income per common share and weighted average common shares outstanding exclude amounts attributed to the unvested restricted class of stockholders. Net income allocated to the unvested restricted stockholders was $2.9 million and $2.5 million for the nine months ended September 30, 2015 and 2014, respectively. Unvested restricted weighted average shares were 3,788 thousand and 3,537 thousand for the nine months ended September 30, 2015 and 2014, respectively.

N/M - Not Meaningful

III. Condensed Consolidated Balance Sheets

(In thousands, unaudited)

December 31, 2014

September 30,2015

Assets

Cash

$ 3,354

$ 22,635

Accounts receivable, net

444,269

574,845

Current deferred tax asset

15,991

23,346

Other current assets

64,030

80,705

Total Current Assets

527,644

701,531

Property and equipment, net

542,310

800,430

Goodwill

1,642,083

2,367,228

Other identifiable intangibles

72,519

258,640

Other assets

140,253

186,576

Total Assets

$ 2,924,809

$ 4,314,405

Liabilities and Equity

Payables and accruals

$ 383,550

$ 504,823

Current portion of long-term debt

10,874

17,666

Total Current Liabilities

394,424

522,489

Long-term debt, net of current portion

1,542,102

2,333,078

Non-current deferred tax liability

109,203

182,963

Other non-current liabilities

92,855

145,277

Total Liabilities

2,138,584

3,183,807

Redeemable non-controlling interests

10,985

257,122

Total equity

775,240

873,476

Total Liabilities and Equity

$ 2,924,809

$ 4,314,405

IV. Condensed Consolidated Statement of Cash Flows

For the Three Months Ended September 30, 2014 and 2015(In thousands, unaudited)

2014

2015

Operating Activities

Net Income

$ 28,296

$ 32,810

Adjustments to reconcile net income to net cash provided by operating activities:

Distributions from unconsolidated subsidiaries

11,939

11,762

Depreciation and amortization

17,584

31,472

Provision for bad debts

10,357

18,287

Equity in earnings of unconsolidated subsidiaries

(1,988)

(6,348)

Gain on sale of assets and businesses

(1,379)

(1,515)

Gain on sale of equity investment

-

(29,647)

Stock compensation expense

3,271

3,450

Amortization of debt discount, premium and issuance costs

1,802

2,719

Deferred income taxes

1,569

(2,497)

Changes in operating assets and liabilities, net of effects from acquisition of businesses:

Accounts receivable

31,325

40,487

Other current assets

3,426

3,458

Other assets

1,195

972

Accounts payable

(8,067)

(5,878)

Accrued expenses

14,069

32,009

Income taxes

(3,325)

(3,170)

Net cash provided by operating activities

110,074

128,371

Investing activities

Purchases of property and equipment

(22,857)

(45,080)

Proceeds from sale of assets

-

1,542

Investment in businesses

(2,960)

(848)

Proceeds from sale of equity investment

-

33,096

Acquisition of businesses, net of cash acquired

(757)

(1,875)

Net cash used in investing activities

(26,574)

(13,165)

Financing activities

Borrowings on revolving facilities

160,000

180,000

Payments on revolving facilities

(230,000)

(275,000)

Borrowings of other debt

925

1,451

Principal payments on other debt

(4,647)

(4,847)

Proceeds from (repayment of) bank overdrafts

13,618

(3,237)

Dividends paid to common stockholders

(13,104)

-

Repurchase of common stock

(1,557)

(13,622)

Proceeds from issuance of common stock

248

279

Proceeds from issuance of non-controlling interest

185

-

Tax benefit from stock based awards

-

372

Distributions to non-controlling interests

(1,279)

(3,158)

Net cash used in financing activities

(75,611)

(117,762)

Net increase (decrease) in cash and cash equivalents

7,889

(2,556)

Cash and cash equivalents at beginning of period

3,140

25,191

Cash and cash equivalents at end of period

$ 11,029

$ 22,635

Supplemental Cash Flow Information

Cash paid for interest

$ 8,675

$ 20,005

Cash paid for taxes

$ 19,713

$ 23,203

V. Condensed Consolidated Statement of Cash Flows

For the Nine Months Ended September 30, 2014 and 2015(In thousands, unaudited)

2014

2015

Operating Activities

Net Income

$ 100,657

$ 110,149

Adjustments to reconcile net income to net cash provided by operating activities:

Distributions from unconsolidated subsidiaries

11,939

11,814

Depreciation and amortization

51,009

70,668

Provision for bad debts

32,490

43,243

Equity in earnings of unconsolidated subsidiaries

(4,135)

(12,788)

Gain on sale of assets and businesses

(1,236)

(1,264)

Gain on sale of equity investment

-

(29,647)

Loss on early retirement of debt

2,277

-

Stock compensation expense

7,391

9,244

Amortization of debt discount, premium and issuance costs

5,651

6,746

Deferred income taxes

2,844

(6,925)

Changes in operating assets and liabilities, net of effects from acquisition of businesses:

Accounts receivable

(52,924)

(48,778)

Other current assets

491

(4,580)

Other assets

(2,267)

4,540

Accounts payable

2,276

3,047

Accrued expenses

(17)

32,716

Income taxes

(4,203)

15,246

Net cash provided by operating activities

152,243

203,431

Investing activities

Purchases of property and equipment

(73,350)

(113,992)

Proceeds from sale of assets

-

1,542

Investment in businesses

(3,135)

(1,703)

Proceeds from sale of equity investment

-

33,096

Acquisition of businesses, net of cash acquired

(1,211)

(1,049,872)

Net cash used in investing activities

(77,696)

(1,130,929)

Financing activities

Borrowings on revolving facilities

675,000

840,000

Payments on revolving facilities

(655,000)

(675,000)

Payments on Select term loans

(33,994)

(26,884)

Issuance of 6.375% senior notes, includes premium

111,650

-

Proceeds from Concentra term loans, net of discounts

-

646,875

Borrowings of other debt

7,036

11,041

Principal payments on other debt

(11,696)

(13,167)

Proceeds from bank overdrafts

10,304

2,353

Debt issuance costs

(4,434)

(23,300)

Dividends paid to common stockholders

(40,257)

(13,129)

Repurchase of common stock

(129,057)

(13,622)

Proceeds from issuance of common stock

5,545

1,604

Proceeds from issuance of non-controlling interest

185

217,065

Distributions to non-controlling interests

(3,119)

(7,440)

Tax benefit from stock based awards

-

383

Net cash provided by (used in) financing activities

(67,837)

946,779

Net increase in cash and cash equivalents

6,710

19,281

Cash and cash equivalents at beginning of period

4,319

3,354

Cash and cash equivalents at end of period

$ 11,029

$ 22,635

Supplemental Cash Flow Information

Cash paid for interest

$ 47,782

$ 59,937

Cash paid for taxes

$ 65,184

$ 55,905

VI. Key Statistics

For the Three Months Ended September 30, 2014 and 2015

(unaudited)

2014

2015

% Change

Specialty Hospitals

Number of hospitals – end of period:

Long term acute care hospitals (a)

113

110

Rehabilitation hospitals (a)

16

17

Total specialty hospitals

129

127

Net operating revenues (,000)

$ 556,335

$ 562,328

1.1%

Number of patient days (b)

332,120

338,412

1.9%

Number of admissions (b)

13,787

13,927

1.0%

Net revenue per patient day (b)(c)

$ 1,543

$ 1,522

(1.4)%

Adjusted EBITDA (,000)

$ 80,950

$ 53,656

(33.7)%

Adjusted EBITDA margin

14.6%

9.5%

Outpatient Rehabilitation

Number of clinics – end of period (d)

1,023

1,033

Net operating revenues (,000)

$ 201,720

$ 199,593

(1.1)%

Number of visits (e)

1,239,932

1,306,637

5.4%

Revenue per visit (e)(f)

$ 103

$ 103

-

Adjusted EBITDA (,000)

$ 23,012

$ 23,807

3.5%

Adjusted EBITDA margin

11.4%

11.9%

Concentra

Number of centers – end of period (g)

300

Net operating revenues (,000)

$ 258,969

Number of visits (g)

1,980,496

Revenue per visit (g)(h)

$ 114

Adjusted EBITDA (,000)

$ 25,584

Adjusted EBITDA margin

9.9%

(a) Includes managed hospitals.

(b) Excludes managed hospitals.

(c) Net revenue per patient day is calculated by dividing specialty hospital direct patient service revenue by the total number of patient days.

(d) Includes managed clinics.

(e) Excludes managed clinics.

(f) Net revenue per visit is calculated by dividing outpatient rehabilitation clinic direct patient service revenue by the total number of visits. For purposes of this computation, outpatient rehabilitation clinic direct patient service revenue does not include managed clinics or contract therapy revenue.

(g) Excludes onsite clinics and community-based outpatient clinics.

(h) Net revenue per visit is calculated by dividing center direct patient service revenue by the total number of center visits.

VII. Key Statistics

For the Nine Months Ended September 30, 2014 and 2015

(unaudited)

2014

2015

% Change

Specialty Hospitals

Number of hospitals – end of period:

Long term acute care hospitals (a)

113

110

Rehabilitation hospitals (a)

16

17

Total specialty hospitals

129

127

Net operating revenues (,000)

$ 1,678,793

$ 1,753,445

4.4%

Number of patient days (b)

1,004,049

1,034,166

3.0%

Number of admissions (b)

41,524

42,352

2.0%

Net revenue per patient day (b)(c)

$ 1,546

$ 1,563

1.1%

Adjusted EBITDA (,000)

$ 261,788

$ 241,575

(7.7)%

Adjusted EBITDA margin

15.6%

13.8%

Outpatient Rehabilitation

Number of clinics – end of period: (d)

1,023

1,033

Net operating revenues (,000)

$ 614,368

$ 603,831

(1.7)%

Number of visits (e)

3,704,504

3,879,409

4.7%

Revenue per visit (e)(f)

$ 104

$ 103

(1.0)%

Adjusted EBITDA (,000)

$ 74,433

$ 74,662

0.3%

Adjusted EBITDA margin

12.1%

12.4%

Concentra

Number of centers – end of period (g)

300

Net operating revenues (,000)

$ 345,798

Number of visits (g)

2,654,330

Revenue per visit (g)(h)

$ 114

Adjusted EBITDA (,000)

$ 36,783

Adjusted EBITDA margin

10.6%

(a) Includes managed hospitals.

(b) Excludes managed hospitals.

(c) Net revenue per patient day is calculated by dividing specialty hospital direct patient service revenue by the total number of patient days.

(d) Includes managed clinics.

(e) Excludes managed clinics.

(f) Net revenue per visit is calculated by dividing outpatient rehabilitation clinic direct patient service revenue by the total number of visits. For purposes of this computation, outpatient rehabilitation clinic direct patient service revenue does not include managed clinics or contract therapy revenue.

(g) Excludes onsite clinics and community-based outpatient clinics.

(h) Net revenue per visit is calculated by dividing center direct patient service revenue by the total number of center visits.

VIII. Net Income to Adjusted EBITDA ReconciliationFor the Three and Nine Months Ended September 30, 2014 and 2015(In thousands, unaudited)

The following table reconciles net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Concentra acquisition costs, equity in earnings (losses) of unconsolidated subsidiaries, and gain on sale of equity investment. The Company believes that the presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of its operating units.

Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles. Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

Three Months Ended September 30,

Nine Months Ended September 30,

2014

2015

2014

2015

Net income

$ 28,296

$ 32,810

$ 100,657

$ 110,149

Income tax expense

17,956

18,347

63,823

65,048

Loss on early retirement of debt

-

-

2,277

-

Interest expense

21,753

33,052

64,032

79,728

Equity in earnings of unconsolidated subsidiaries

(1,988)

(6,348)

(4,135)

(12,788)

Gain on sale of equity investment

-

(29,647)

-

(29,647)

Stock compensation expense:

Included in general and administrative

2,650

3,433

5,840

8,073

Included in cost of services

549

1,392

1,479

2,402

Depreciation and amortization

17,584

31,472

51,009

70,668

Concentra acquisition costs

-

-

-

4,715

Adjusted EBITDA

$ 86,800

$ 84,511

$ 284,982

$ 298,348

Specialty hospitals

$ 80,950

$ 53,656

$ 261,788

$ 241,575

Outpatient rehabilitation

23,012

23,807

74,433

74,662

Concentra

-

25,584

-

36,783

Other (a)

(17,162)

(18,536)

(51,239)

(54,672)

Adjusted EBITDA

$ 86,800

$ 84,511

$ 284,982

$ 298,348

(a) Other primarily includes general and administrative costs.

IX. Reconciliation of Income Per Common Share to Adjusted Income Per Common Share

For the Nine Months Ended September 30, 2014 and 2015

(In thousands, except per share amounts, unaudited)

2014

Per Share (a)

2015

Per Share (a)

Net income attributable to Select Medical Holdings Corporation

$ 94,915

$ 101,409

Earnings allocated to unvested restricted stockholders

(2,519)

(2,925)

Net income available to common stockholders

92,396

$ 0.71

98,484

$ 0.77

Adjustment for early retirement of debt:

Loss on early retirement of debt

2,277

0.02

-

-

Estimated income tax benefit (b)

(925)

(0.01)

-

-

Earnings allocated to unvested restricted stockholders

(36)

(0.00)

-

-

Adjusted net income available to common stockholders

$ 93,712

$ 0.72

$ 98,484

$ 0.77

Adjustment for dilution

(0.00)

(0.00)

Adjusted income per common share - diluted shares

$ 0.72

$ 0.77

Weighted average common shares outstanding:

Basic

129,706

127,541

Diluted

130,177

127,844

(a) Per share amounts for each period presented are basic weighted average common shares outstanding for all amounts except adjusted income per common share - diluted shares, which is based on diluted shares outstanding.

(b) Represents the estimated tax benefit on the adjustments to net income.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/select-medical-holdings-corporation-announces-results-for-third-quarter-ended-september-30-2015-300169004.html

SOURCE Select Medical Holdings Corporation

Categories

Press Releases

Next Articles